#1 Clinical Trials Search in Europe

MAGNESIUM ACETATE TETRAHYDRATE

Clinical trials investigating MAGNESIUM ACETATE TETRAHYDRATE are studying how this substance is used in research settings and which patients may be included. The available trial data focus on treatment effects, safety-related outcomes, and patient groups such as people on hemodialysis or with other serious medical conditions.

Table of contents

Trials overview

The provided trial data include two interventional studies, which means the researchers are testing a treatment and then measuring the results in patients.[1][2]

Both studies are Phase 3 and are marked as authorised.[1][2]

The records focus on serious medical situations, including chronic hemodialysis and critical illness with kidney problems.[1][2]

Study 1: LOTUS

The first trial is called LOTUS and has the ID 2025-522111-42-02.[1]

It is a Phase 3 interventional study with an enrollment of 20 participants.[1]

The study is being done in people with chronic hemodialysis, which means patients whose blood is regularly cleaned by a dialysis machine because their kidneys do not work well enough.[1]

The brief summary says the study aims to see the effect of IDPN on muscle protein synthesis in chronic hemodialysis patients and to describe the hemodynamic effects of IDPN.[1]

The main endpoint is the difference in myofibrillar fractional synthetic rate during one week of treatment with IDPN versus control.[1]

Study 2: Kidney outcomes in critical illness

The second trial has the ID 2025-523914-10-00 and is also a Phase 3 interventional study.[2]

It includes 660 participants and focuses on metabolic acidosis, critical illness, and acute kidney injury.[2]

The brief summary says the study is investigating the effect of sodium bicarbonate on major adverse kidney events at day 90.[2]

The primary outcome is MAKE90, a combined endpoint that includes death, any kidney replacement therapy within 90 days after randomization, or persistent renal dysfunction at day 90.[2]

The intervention list includes several infusion solutions and sodium hydrogen carbonate, which shows that this study compares treatment options given by intravenous infusion.[2]

What the endpoints mean

An endpoint is the main result researchers measure to see whether a treatment helps.[1][2]

In the LOTUS study, the endpoint measures how fast muscle protein is being made, which helps researchers understand muscle building in dialysis patients.[1]

In the kidney study, the endpoint combines several serious outcomes into one measure so researchers can see whether treatment lowers the risk of major kidney problems.[2]

Who the trials are for

The LOTUS trial is for people on chronic hemodialysis, a group that often has complex nutrition and muscle health needs.[1]

The second trial is for critically ill patients who have metabolic acidosis and acute kidney injury, which are both serious conditions seen in hospitals.[2]

These trial records do not provide full eligibility rules, so the exact inclusion and exclusion criteria are not shown in the source data.[1][2]

What patients should know

The available records show that the research is still in the testing stage and is focused on specific patient groups rather than the general population.[1][2]

The data do not give detailed results yet, so these entries describe what the studies are designed to measure, not what they have already found.[1][2]

Because the source data are limited, the article can only summarize the trial aims, phases, populations, and endpoints that are listed here.[1][2]

Trial ID Phase Condition studied Status Enrollment
2025-522111-42-02 Phase 3 Muscle protein turnover, hemodialysis Authorised 20
2025-523914-10-00 Phase 3 Metabolic acidosis, critical illness, acute kidney injury Authorised 660

FAQ

  • What is being studied in trials of MAGNESIUM ACETATE TETRAHYDRATE? The trial data provided do not show a direct study of MAGNESIUM ACETATE TETRAHYDRATE itself. The listed studies focus on clinical outcomes in specific patient groups, such as muscle protein turnover in hemodialysis patients and kidney outcomes in critically ill patients.
  • Who may take part in these trials? The target groups include chronic hemodialysis patients and critically ill patients with metabolic acidosis and acute kidney injury. Each trial has its own eligibility rules, so participation depends on the study design.
  • What trial phases are listed? Both trials in the provided data are Phase 3 studies. Phase 3 trials usually test whether a treatment works in a larger group of patients and measure important clinical outcomes.
  • What outcomes are the trials measuring? One trial measures the difference in myofibrillar fractional synthetic rate, which is a marker of muscle protein building. The other trial measures major adverse kidney events at 90 days, including death, kidney replacement therapy, or persistent kidney dysfunction.
  • How many trials are included in the data? Two clinical trials are listed. Both are interventional studies and both are currently marked as authorised.

Ongoing Clinical Trials on MAGNESIUM ACETATE TETRAHYDRATE

  • Effect of sodium hydrogen carbonate on kidney health in critically ill patients with metabolic acidosis and acute kidney injury

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of Intradialytic Parenteral Nutrition for Muscle Protein Production in Patients on Long-term Hemodialysis Treatment

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Clinical trial: A planned research study in people. It is used to test whether a treatment or approach is effective and safe.
  • Phase 3: A later stage of clinical research. It usually involves more patients and looks at how well a treatment works in real-world-like conditions.
  • Interventional study: A study where researchers give a treatment or compare treatments and then measure the results.
  • Hemodialysis: A treatment that cleans the blood when the kidneys are not working well.
  • Muscle protein turnover: The process of building and breaking down muscle protein in the body.
  • Myofibrillar fractional synthetic rate: A measure of how fast muscle protein is being made. It is used in research to study muscle building.
  • Metabolic acidosis: A condition where the blood is too acidic. It can happen in serious illness or kidney problems.
  • Acute kidney injury: A sudden loss of kidney function that happens over a short time.
  • KRT: Kidney replacement therapy. This includes treatments that help do the work of damaged kidneys, such as dialysis.
  • Major adverse kidney events (MAKE90): A combined outcome used in research. It can include death, need for kidney replacement therapy, or lasting kidney problems by day 90.

References

  1. https://clinicaltrials.gov/study/2025-522111-42-02
  2. https://clinicaltrials.gov/study/2025-523914-10-00